辉瑞第三季度营收 166.5 亿美元，预估 165.9 亿美元
Pfizer's revenue for the third quarter was $16.65 billion, exceeding the estimated $16.59 billion. The adjusted earnings per share were $0.87, with a full-year revenue forecast of $61 billion to $64 billion, and the adjusted earnings per share expectation raised to $3 to $3.15. Pfizer's stock rose over 2% in pre-market trading
Pfizer's adjusted earnings per share for the third quarter were $0.87. Pfizer still forecasts full-year revenue of $61 billion to $64 billion. Pfizer expects full-year adjusted earnings per share of $3 to $3.15, up from the previous estimate of $2.90 to $3.10. Pfizer's U.S. stock rose more than 2% in pre-market trading.
Risk Warning and Disclaimer
The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at your own risk
